Physician profile
Steve Hou
NPI 1245450204
$11,260.86
in general payments reported to CMS, 2019-2025
30 companies · $2,914 in 2025
The $2,914 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,448 · 2020: $156 · 2021: $1,214 · 2022: $58.23 · 2023: $1,422 · 2024: $2,049 · 2025: $2,914.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,302 · Education: $83.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,301.50 |
| Education | $83.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $3,151.02 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,051.36 | 2019-2025 | Airsupra, Breztri |
| Lilly USA, LLC | $921.06 | 2019-2025 | Jardiance, Mounjaro, Kisunla |
| Abbvie INC. | $710.17 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $672.64 | 2019-2025 | Jardiance, Synjardy |
| Merck Sharp & Dohme LLC | $627.61 | 2019-2025 | Belsomra, Gardasil 9, Capvaxive |
| Amarin Pharma, INC. | $528.02 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $457.73 | 2023-2025 | |
| Amgen INC. | $452.64 | 2019-2025 | Repatha |
| Novo Nordisk INC | $432.65 | 2019-2025 | Rybelsus, Ozempic |
| Phathom Pharmaceuticals, INC. | $356.19 | 2024-2025 | Voquezna |
| Allergan, INC. | $306.20 | 2019 | |
| Janssen Pharmaceuticals, INC | $218.50 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $205.75 | 2019 | |
| Eisai INC. | $143.85 | 2024-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $125.00 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $121.10 | 2025 | Xifaxan |
| Medtronic, INC. | $98.16 | 2025 | Closurefast |
| Glaxosmithkline, LLC. | $94.37 | 2023-2024 | Arexvy, Shingrix |
| Pfizer INC. | $84.98 | 2019-2025 | |
| Intra-Sana Laboratories | $78.76 | 2023 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Akebia Therapeutics INC | $62.88 | 2019 | |
| Seqirus USA INC | $61.97 | 2021 | |
| Smith+Nephew, INC. | $58.71 | 2024-2025 | Collagenase Santyl |
| Exact Sciences Corporation | $57.25 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $48.94 | 2023-2024 | Veozah |
| Calliditas Therapeutics US INC. | $38.50 | 2022-2023 | Tarpeyo |
| Kowa Pharmaceuticals America, INC. | $36.21 | 2024-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $35.48 | 2023 | |
| Shield Therapeutics INC | $23.16 | 2023 | Accrufer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steve Hou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.